SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26: 3246.
  • 2
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 3
    Esmon NL, Safa O, Smirnov M, Esmon CT. Antiphospholipid antibodies and the protein C pathway. J Autoimmun 2000; 15: 2215.
  • 4
    Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73: 52934.
  • 5
    Roubey RA. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7: S1149.
  • 6
    Meroni PL, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheumatol 2001: 13: 37782.
  • 7
    Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 84954.
  • 8
    Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 28949.
  • 9
    Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 132832.
  • 10
    Dobado-Barrios M, Lopez-Pedrera C, Velasco F, Aguirre MA, Torres A, Cuadrado MJ. Increased levels of TF mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82: 157882.
  • 11
    Martini F, Farsi A, Gori AM, Boddi M, Fedi S, Domeneghetti MP, et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus 1996; 5: 20611.
  • 12
    Reverter JC, Tassies D, Font J, Khamashta MA, Ichikawa K, Cervera R, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41: 14207.
  • 13
    Reverter JC, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M, et al. Hypercoagulable state in patients with the antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996; 16: 131926.
  • 14
    Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 83441.
  • 15
    Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate vascular endothelial cells. Lupus 1996; 5: 4401.
  • 16
    Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15: 23740.
  • 17
    Pierangeli SS, Liu XW, Anderson GH, Barker JH, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74: 13617.
  • 18
    Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GH, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 19972000.
  • 19
    Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003; 1: 8438.
  • 20
    Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 24550.
  • 21
    Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 18.
  • 22
    Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB. Thromb Haemost 1997; 77: 77282.
  • 23
    Haddad JJ, Fahlman CS. Nuclear factor κB independent regulation of lipopolysaccharide-mediated interleukin-6 biosynthesis. Biochem Biophys Res Commun 2002; 291: 104551.
  • 24
    Louise CB, Tran MC, Obrig TG. Sensitization of human umbilical vein endothelial cells to Shiga toxin: involvement of protein kinase C and NF-κB. Infect Immun 1997; 65: 333744.
  • 25
    Dunoyer-Geindre S, de Moerloose P. Galve-de Rochemonteix B, Reber G, Kruithof EK. NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein I antibodies. Thromb Haemost 2002: 88: 8517.
  • 26
    Herlaar E, Brown Z. p38 MAPK signaling cascades in inflammatory disease. Mol Med Today 1999; 5: 43947.
  • 27
    Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 113.
  • 28
    Cohen P. The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol 1997; 7: 35361.
  • 29
    Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50: 29119.
  • 30
    Morikawa A, Koide N, Kato Y, Sugiyama T, Chakravortty D, Yoshida T, et al. Augmentation of nitric oxide production by γ interferon in a mouse vascular endothelial cell line and its modulation by tumor necrosis factor α and lipopolysaccharide. Infect Immun 2000; 68; 620914.
  • 31
    Chan E, Winston BW, Uh ST, Wynes, MW, Rose DM, et al. Evaluation of the role of mitogen-activated protein kinases in the expression of inducible nitric oxide synthase by IFN-γ and TNF-α in mouse macrophages. J Immunol 1999; 162: 41522.
  • 32
    Da Silva J, Pierrat B, Mary JL, Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. J Biol Chem 1997; 272: 2837380.
  • 33
    Ferrara DE, Swerlick R, Casper K, Meroni PL, Vega-Ostertag ME, Harris EN, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thomb Haemost 2004; 2: 155863.
  • 34
    Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95105.
  • 35
    Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: 19.
  • 36
    O'Reilly FM, Casper KA, Otto KB, Sexton SA, Swerlick RA. Regulation of tissue factor in microvascular dermal endothelial cells. J Invest Dermatol 2003; 120: 48994.
  • 37
    Zhou H, Woldberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 23538.
  • 38
    Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 27681.
  • 39
    Rustin MH, Bull HA, Machin SJ, Isenberg DA, Snaith S, Dowd PM. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 1988; 90: 7448.
  • 40
    Branch DW, Rodgers G. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 20610.
  • 41
    Semerato N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 75964.
  • 42
    Osterud B, Bjordlid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 60517.
  • 43
    Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu XW, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vitro and in vivo. J Immunol 1999; 163: 29227.
  • 44
    Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Forusaki A, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2-glycoprotein I antibodies. Int Immunol 2004; 16: 163341.
  • 45
    Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti–β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial cells activation. Arthritis Rheum 1997; 40: 55161.
  • 46
    Del Papa N, Sheng YH, Raschi E, Kandiah DA, Tincani A, Khamashta MA, et al. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipids binding and offers epitopes for anti-β2-glycoprotein antibodies. J Immunol 1998; 160: 55728.
  • 47
    Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High-affinity binding of β2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275: 155418.
  • 48
    Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-β2-glycoprotein I antibodies. Blood 2004. E-pub ahead of print.
  • 49
    Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of MYD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495500.
  • 50
    Khamashta MA, Cuadrado MJ, Mujic T, Taub NA, Hunt BM, Hughes GR. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 9937.
  • 51
    Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med 1997; 157: 21018.
  • 52
    Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 11338.
  • 53
    Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAPK as a therapeutic strategy. Immunopharmacology 2000; 47: 185201.
  • 54
    Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, et al. Inhibition of coagulation, fibrinolysis and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003; 101: 44468.
  • 55
    Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griwold DE. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in an animal model of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279: 145361.